BioCentury
ARTICLE | Company News

Blackstone, Novartis spin out cardiovascular newco Anthos

February 27, 2019 7:38 PM UTC

Leading its first deal since acquiring Clarus Ventures, Blackstone has partnered with Novartis AG (NYSE:NVS; SIX:NOVN) to launch Anthos Therapeutics Inc. (Cambridge, Mass.) with $250 million and Novartis antithrombotic MAA868.

In exchange for the compound, Novartis will retain an undisclosed minority stake in the company...